A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Inclusion Criteria: * Has a confirmed diagnosis of solid tumor for one of the following types of cancer: previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC HER2-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, or platinum-resistant ovarian cancer. * Has metastatic disease that has progressed during or following previous treatment appropriate for the disease type * Presence of radiographically measurable disease. * Is willing to provide tumor tissue * Has adequate organ function * Has a negative test or adequate therapy for human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C. * Has completed all prior therapy. * Female subjects of childbearing potential must have a negative serum pregnancy test. * Both male and female subjects must be willing to use adequate contraception. Exclusion Criteria: * Has peripheral neuropathy of Grade \>1. * Has a malignancy involving the central nervous system. * Has another major cancer. * Has an uncontrolled ongoing infection. * Has significant cardiovascular disease. * Has a known diagnosis of liver cirrhosis. * Is pregnant or breastfeeding. * Has had major surgery within 4 weeks before the start of study therapy. * Has known tumor resistance or intolerance to a prior MMAE-containing drug. * Is concurrently participating in another therapeutic or imaging clinical trial.